Report from the 2018 consensus conference on immunomodulating agents in thoracic transplantation: Access, formulations, generics, therapeutic drug monitoring, and special populations
Report from the 2018 consensus conference on immunomodulating agents in thoracic transplantation: Access, formulations, generics, therapeutic drug monitoring, and special populations
复制标题
DOI：
10.1016/j.healun.2020.06.024
复制
发表时间：
2020-10-01
影响因子：
8.9
通讯作者：
Page, Robert L., II
中科院分区：
文献类型：
--
作者：
Cochrane, Adam B.;Lyster, Haifa;Page, Robert L., II
2009年，国际心脏和肺移植学会认识到围绕仿制药免疫抑制的重要性和挑战。随着仿制药经验的扩大和舒适度的提高，自那时以来，免疫调节的其他方面出现了大量问题，这些问题尚未得到解决，例如药物的获得，替代免疫抑制制剂，其他仿制药，对治疗药物监测的影响以及对特殊人群（如儿科和老年人）的影响。本共识文件的目的是批判性地解决这些问题，扩大挑战和障碍，并为管理需要接受或已经接受心胸移植的患者的从业人员提供治疗考虑。(C)2020年国际心肺移植学会。All rights reserved.
In 2009, the International Society for Heart and Lung Transplantation recognized the importance and challenges surrounding generic drug immunosuppression. As experience with generics has expanded and comfort has increased, substantial issues have arisen since that time with other aspects of immunomodulation that have not been addressed, such as access to medicines, alternative immunosuppression formulations, additional generics, implications on therapeutic drug monitoring, and implications for special populations such as pediatrics and older adults. The aim of this consensus document is to address critically each of these concerns, expand on the challenges and barriers, and provide therapeutic considerations for practitioners who manage patients who need to undergo or have undergone cardiothoracic transplantation. (C) 2020 International Society for Heart and Lung Transplantation. All rights reserved.